Regen BioPharma, Inc. (OTCMKTS:RGBP – Get Free Report) saw a large drop in short interest in October. As of October 15th, there was short interest totaling 138,853 shares, a drop of 53.3% from the September 30th total of 297,566 shares. Based on an average daily volume of 7,295,221 shares, the short-interest ratio is currently 0.0 days.
Regen BioPharma Stock Performance
Shares of OTCMKTS RGBP opened at $0.00 on Friday. Regen BioPharma has a 52 week low of $0.00 and a 52 week high of $0.02.
About Regen BioPharma
Regen BioPharma, Inc is a biotechnology company focused on developing regenerative medicine and immunotherapy applications. The company has historically described its work as targeting conditions involving bone marrow failure, cancer and immune-system dysfunction.
Its reported research programs have included HemaXellerate, an investigational approach intended to support the restoration of blood-forming cells, as well as programs involving cancer vaccines, immune modulation and the NR2F6 biological pathway.
See Also
- Five stocks we like better than Regen BioPharma
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Regen BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regen BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
